Tokyo - Delayed Quote JPY
Delta-Fly Pharma, Inc. (4598.T)
647.00
+44.00
+(7.30%)
At close: May 30 at 3:30:00 PM GMT+9
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
0
0
0
300,000
300,000
Operating Expense
1,403,463
1,403,463
1,315,809
1,261,462
1,152,231
Operating Income
-1,403,463
-1,403,463
-1,315,809
-961,462
-852,231
Net Non Operating Interest Income Expense
-17,642
-17,642
-4,194
-1,809
-3,927
Pretax Income
-1,426,891
-1,426,891
-1,325,760
-964,064
-859,372
Tax Provision
2,502
2,502
3,028
3,237
3,213
Net Income Common Stockholders
-1,429,393
-1,429,393
-1,328,788
-967,302
-862,585
Diluted NI Available to Com Stockholders
-1,429,393
-1,429,393
-1,328,788
-967,302
-862,585
Basic EPS
-198.78
--
-234.51
-178.58
-187.34
Diluted EPS
-198.78
--
-234.51
-178.58
-187.34
Basic Average Shares
7,190.97
--
5,666.27
5,416.67
4,604.28
Diluted Average Shares
8,229.70
--
5,666.27
5,416.67
4,604.28
Total Operating Income as Reported
-1,403,464
-1,403,464
-1,315,810
-961,462
-852,231
Total Expenses
1,403,463
1,403,463
1,315,809
1,261,462
1,152,231
Net Income from Continuing & Discontinued Operation
-1,429,393
-1,429,393
-1,328,788
-967,302
-862,585
Normalized Income
-1,429,393
-1,429,393
-1,328,788
-967,302
-862,585
Interest Income
14
14
13
70
227
Interest Expense
--
--
--
0
43
Net Interest Income
-17,642
-17,642
-4,194
-1,809
-3,927
EBIT
-1,403,463
-1,403,463
-1,315,809
-961,462
-859,329
EBITDA
-1,401,951
-1,401,951
-1,314,177
-959,790
-857,324
Reconciled Depreciation
1,512
1,512
1,632
1,672
2,005
Net Income from Continuing Operation Net Minority Interest
-1,429,393
-1,429,393
-1,328,788
-967,302
-862,585
Normalized EBITDA
-1,401,951
-1,401,951
-1,314,177
-959,790
-857,324
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
3/31/2021 - 10/12/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade